American Journal of BioMedicine Volume 2, Issue 10,
Shu-Peng Zheng; Xiang Feng; Yi Liul
Androgen receptor mediated transcription and function in prostate cancer and critical for prostate cell growth and gland differentiation. Transducin beta like related protein 1 (TBLR1) primarily localizes in the nucleus in benign prostate tissue and is significantly reduced in prostate cancer. The objective of this study is investigated the role of cytoplasmic TBLR1in prostate cancer. Real-time PCR, Western blotting and immunocytochemistry were used to evaluate Transducin beta like related protein 1 (TBLR1) expression in prostate cancer cell lines and normal prostate cells, tissue samples and adjacent nontumor tissues, and in 142 paraffin-embedded specimens. Immunohistochemical analysis revealed high expression of TBLR1 in 89 of 214 paraffin-embedded archival prostate cancer. The expression level of TBLR1 was significantly increased in prostate cancer both in vivo and in vitro and correlated with clinical stage (P<0.05) and metastasis (P<0.001). Over all the study showed that the TBLR1 plays a key role in the development of prostate cancer cells and TBLR1 may be prognostic marker and a potential therapeutic target in the treatment human prostate cancer.
Keywords: Prostate cancer; Androgen receptor; TBLR1; Real-time PCR
1. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J: Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 2003; 22(6):1336-1346. [PubMed]
2. American Cancer Society (2013) Prostate Cancer.
3. European Commission Eurostat (2013) European shortlist of causes of death.
4. Herrmann C, Cerny T, Savidan A, et al. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer 2013;13: 287. [PubMed]
5. Breslow N, Day N (1987) Statistical methods in cancer research. Volume II – The design and analysis of cohort studies. 406 p.
6. Wallner LP, Wang R, Jacobsen SJ, Haque R. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev 2013; 22: 313–316. [PubMed]
7. Alhasani S, Yousif NG. Critical role of IL-23 signaling in prostatic cancer. American Journal of BioMedicine 2013; 1(1):4-6. [Abstract/Full-Text]
8. Garrett D. TBLR1, an androgen receptor coactivator, regulates prostate cancer growth.Ph.D. Thesis, NEW YORK UNIVERSITY, 2013, 188 pages; 3591189 [Abstract]
10. Nash GF, Turner KJ, Hickish T, et al. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl 2012; 94: 456–462. [PubMed]
11. Li J, Wang CY: TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nature Cell Biol 2008; 10(2):160-169. [Full Text]
12. Kulozik P, Jones A, Mattijssen F, et al. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab 2011; 13(4):389-400. [Full Text]
13. Sharma D and Fondell JD. Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone‐responsive promoters in vivo. Proc Natl Acad Sci USA 2002; 99: 7934–7939. [ ]
15. Van Hemelrijck M, Drevin L, Holmberg L. et al. Primary cancers before and after prostate cancer diagnosis. Cancer 2012; 118: 6207–6216. [PubMed]
16. Murray L, Henry A, Hoskin P, et al.. (2014) Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. Radiother Oncol.